Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22229640 | 1.00 | ROCK2 (0.35) | ROCK2CYP19A1CYP11B1CYP11B2SCN9A | |
| SCHEMBL22229617 | 0.89 | GRM4 (0.31) | SCN9A | |
| SCHEMBL30189449 | 0.89 | GRM4 (0.31) | SCN9A | |
| SCHEMBL22229645 | 0.88 | ROCK2 (0.35) | ROCK2 | |
| SCHEMBL22229646 | 0.88 | ROCK2 (0.39) | ROCK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL22229559 | 0.88 | ROCK2 (0.37) | ROCK2CYP19A1CYP11B2 | |
| SCHEMBL22229600 | 0.88 | ROCK2 (0.39) | ROCK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL22229598 | 0.88 | ROCK2 (0.35) | ROCK2 | |
| SCHEMBL20769748 | 0.88 | ROCK2 (0.35) | ROCK2CYP19A1 | |
| SCHEMBL30189562 | 0.88 | ROCK2 (0.37) | ROCK2CYP19A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ANGION BIOMEDICA CORP. (US) | 2023-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885CYP19A1 2057/4885CYP11B1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.